The International journal of eating disorders

Activating GLP-1 Receptors Increases Activity-Based Anorexia in Mice

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated

Abstract

GLP-1 receptor (GLP-1R) agonists may influence weight loss and activity levels in anorexia nervosa.

  • GLP-1R agonists are known to reduce food intake and body weight.
  • Preclinical findings suggest that these drugs could decrease activity and reward-seeking behavior.
  • There is a possibility that GLP-1R agonists may reduce compulsive-like hyperactivity associated with activity-based anorexia.
  • The effects of GLP-1R agonists on weight loss and hyperactivity in a rodent model of anorexia nervosa are being investigated.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Related papers

Dec '18
Improved GIP-like drugs reduce body weight in mice by activating, not blocking, GIP receptors
top 5% journal
cited by 206 papers
research support, non-u.s. gov't
Aug '17
Control of Eating and Reward by a Thalamus Area Involving Glucagon-Like Peptide-1 Receptors
top 5% journal
cited by 104 papers
journal article
Nov '24
Loss of a specific signaling in inhibitory brain cells increases weight loss caused by GLP-1 receptor drugs
top 5% journal
cited by 19 papers
journal article
Mar '24
Loss of GIP receptor in leptin receptor cells reduces glucose control by GIP and GIP-GLP-1 combination without changing body weight or food intake in mice
top 5% journal
cited by 11 papers
research support, non-u.s. gov't
Jan '13
Brain signals that reduce appetite through sugar metabolism need lower AMPK activity and are weakened by fructose in the brain
top 10% journal
cited by 60 papers
research support, non-u.s. gov't
Jul '18
Combined Effects of Glucagon and GLP-1 Drugs in Obese Diabetic Monkeys
top 10% journal
cited by 22 papers
research support, non-u.s. gov't
Feb '26
Activating liver GLP-1 receptors may improve weight loss with GLP-1 drugs
top 5% journal
journal article
Jan '12
How nausea relates to reduced eating and weight loss from injected GLP-1 drugs exendin-4 and liraglutide
top 10% journal
cited by 252 papers
research support, n.i.h., extramural

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
2 days ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
1 week ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
2 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
3 weeks ago7 studies
issue #44
Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study
4 weeks ago7 studies
issue #43
Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients
5 weeks ago7 studies
issue #42
Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group
6 weeks ago8 studies
issue #41
New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients
7 weeks ago7 studies
issue #40
GLP-1 users had 3x higher risk of aspiration pneumonia after stroke surgery
8 weeks ago7 studies
issue #39
Semaglutide linked to reduced cigarette craving in 24 smokers
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief